Treating Androgenic Alopecia with groMD shampoo

Androgenic alopecia (AGA), often referred to as male or female pattern baldness, affects tens of millions of individuals worldwide. AGA is in part genetically determined and is potentially reversible. With AGA, one experiences miniaturization of the hair follicles and shortening of the anagen (growth) phase in the involved hairs.

The main androgen responsible for these changes to the hair follicle is dihydrotestosterone (DHT). Testosterone is converted to DHT by an enzyme, 5-alpha reductase (5AR).

Most treatment modalities for AGA are overall not significantly effective. The high prevalence of AGA, significant early age of onset, and large degree of associated psychosocial morbidity have created a large market for AGA treatment.

Despite the paramount demand for AGA treatment, there are only two FDA-approved medications, minoxidil (Rogaine) and finasteride (Propecia). However, they are costly, require lifelong treatment, and may have negative side effects. GroMD products are simple and easy-to-use, free of sulfates, parabens, and other harmful chemicals, so everyone can adopt a light daily regimen that prevents hair loss.

GroMD’s fortified and expertly refined DHT-blocking formula is enriched with growth-factor peptides and proteins, as well as anti-inflammatory mediators and anagen growth stimulators. The goal of treating AGA is to stop active hair loss, prevent further loss and retain existing hair. If possible, an attempt to reactivate the hair follicle and to stimulate new hair growth should be undertaken.

In a pilot study on the efficacy of groMD in treating AGA conducted in 2019, all participants that used groMD shampoo and groMD Follicle Activator Spray (groMD system) over the span of 12 months demonstrated deceleration of hair loss and new hair growth. During the 12-month open, randomized, double-blind and controlled treatment phase, a significant difference in relation to the main parameters of hair growth could be found between the treatment groups. 

Treatment with the groMD system led to a significant increase of thickness and density in comparison to baseline levels at the beginning of the clinical trial.